Who are atorvastatin, aspirin, losartan, amlodipine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/atorvastatin-aspirin-losartan-amlodipine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

atorvastatin, aspirin, losartan, amlodipine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

atorvastatin, aspirin, losartan, amlodipine (atorvastatin, aspirin, losartan, amlodipine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fixed-dose combination: HMG-CoA reductase inhibitor, antiplatelet agent, angiotensin II receptor antagonist, and calcium chan

marketed Fixed-dose combination: HMG-CoA reductase inhibitor, antiplatelet agent, angiotensin II receptor antagonist, and calcium channel blocker Multiple: HMG-CoA reductase, cyclooxygenase, AT1 receptor, L-type calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

atorvastatin, aspirin, losartan, amlodipine (atorvastatin, aspirin, losartan, amlodipine) — Russian Cardiology Research and Production Center. This is a fixed-dose combination of four cardiovascular agents that work synergistically to reduce cholesterol, prevent thrombosis, lower blood pressure, and improve coronary blood flow.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
atorvastatin, aspirin, losartan, amlodipine TARGET	atorvastatin, aspirin, losartan, amlodipine	Russian Cardiology Research and Production Center	marketed	Fixed-dose combination: HMG-CoA reductase inhibitor, antiplatelet agent, angiotensin II receptor antagonist, and calcium channel blocker	Multiple: HMG-CoA reductase, cyclooxygenase, AT1 receptor, L-type calcium channel

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fixed-dose combination: HMG-CoA reductase inhibitor, antiplatelet agent, angiotensin II receptor antagonist, and calcium channel blocker class)

Russian Cardiology Research and Production Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). atorvastatin, aspirin, losartan, amlodipine — Competitive Intelligence Brief. https://druglandscape.com/ci/atorvastatin-aspirin-losartan-amlodipine. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab